Tag: inflammation

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...
1. In this secondary analysis of data from the CANTOS trial in 2017, canakinumab significantly reduced the incidence of anemia in patients with a history of myocardial infarction. 2. Among participants with baseline anemia, those who received canakinumab had significantly higher hemoglobin levels versus placebo. Evidence Rating Level: 3 (Average) Study Rundown:...
Image: PD 1. Elevated levels of CRP, fibrinogen, and leukocyte count are associated with an increased risk of COPD exacerbations over one year. 2. There was a stepwise increase in the risk of frequent exacerbations over the 1, 3, and 5 year follow-up period based upon the number of biomarkers present. Evidence...